ADC Therapeutics vs Bicycle Therapeutics
ADCT and BCYC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADCT and BCYC compare
Bicycle Therapeutics is the larger company, worth 1.4 times as much as ADC Therapeutics ($236M against $171M).
Bicycle Therapeutics grew revenue faster over the last twelve months (195% versus 12.8% for ADC Therapeutics).
ADC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −95.7% compared with −170% at Bicycle Therapeutics.
Bicycle Therapeutics scores higher on the StockData Score (11 against 4 for ADC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADCT | BCYC |
|---|---|---|
| Size and price | ||
| Market cap | $171M | $236M |
| Share price | $1.34 | $3.37 |
| Change, 1 year | −66.9% | −48.6% |
| Change, 5 years | −94.1% | −94.2% |
| Beta (5Y) | 1.96 | 1.37 |
| Employees | 188 | 288 |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.0× (better) | 2.8× |
| P/B | – | 0.5× |
| FCF yield | −58.8% (better) | −74.9% |
| Fair value | – | $16.02 |
| Margin of safety | – | 79.0% |
| Growth | ||
| Revenue growth (TTM) | 12.8% | 195% (better) |
| Revenue growth, 5Y average | – | 47.5% |
| Profitability | ||
| Operating margin | −97.7% (better) | −189% |
| Net margin | −95.7% (better) | −170% |
| FCF margin | −118% (better) | −212% |
| Return on equity | – | −25.2% |
| Return on invested capital | – | −4543% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1.6× (better) | −815.6× |
| Current ratio | 3.05 | 12.09 (better) |
| Altman Z-score | −9.14 | 0.04 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | −25.0% | – |
| Shareholder yield | −25.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.9% | 53.4% |
| Held by insiders | 42.8% | 21.3% |
| Insider net buying, 12 months | −$19.6M | −$523K (better) |
| Short interest, % of float | 8.8% | – |
Go deeper
- ADCT stock overview
- ADCT income statement
- ADCT valuation and score
- BCYC stock overview
- BCYC income statement
- BCYC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.